Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2018-01668 | Registry Identifier | CTRP (Clinical Trial Reporting Program) | |
| 17-001785 | Other Identifier | UCLA / Jonsson Comprehensive Cancer Center |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This trial studies the side effects of OsteoCrete in filling bone voids in participants with bone voids or defects. OsteoCrete may eliminate the need for further surgery and the removal of healthy bone.
PRIMARY OBJECTIVES:
I. To assess the safety of the device, which for the purpose of this study is defined as the compound injected into bone.
SECONDARY OBJECTIVES:
I. To determine the rate of absorption and bone ingrowth.
OUTLINE:
Participants receive OsteoCrete intraoperatively to fill voids that occur in bones during surgery or to augment screw fixation.
After completion of study treatment, participants are followed for up to 1 year.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment (OsteoCrete) | Experimental | Participants receive OsteoCrete intraoperatively to fill voids that occur in bones during surgery or to augment screw fixation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Magnesium-based Bone Void Filler | Other | Given intraoperatively |
|
| Measure | Description | Time Frame |
|---|---|---|
| Participants reaching one year post-op and completing all study visits | Up to 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Amount of reabsorption and bone ingrowth | Will be measured in Hounsfield units by X-ray and compute tomography (CT). | Up to 1 year |
| Incidence of adverse events rates | Will be coded by body system and MedDra classification term. Adverse events will be tabulated by treatment group and will include the number of patients for whom the event occurred, the rate of occurrence, and the severity and relationship to study device. |
Not provided
Inclusion Criteria:
Documentation of a diagnosis as evidenced by one or more clinical features consistent with one or more of the following criteria:
Written informed consent (and assent when applicable) obtained from subject or subject?s legal representative and ability for subject to comply with the requirements of the study.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Francis Hornicek | UCLA / Jonsson Comprehensive Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | United States |
Not provided
| ID | Term |
|---|---|
| C542722 | OsteoCrete |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to 1 year |